Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

Arch Biopartners Doses First Patient in Phase II AKI Trial Amidst Dilution Concerns

By The Northwire Desk — AI Analysis May 22, 2026 · 06:50 ARCH · 0.445 Arch Biopartners Inc.
Executive Summary
  • Royal Columbian Hospital (RCH) has dosed its first patient in Arch Biopartners' ongoing Phase II clinical trial for LSALT peptide.
  • The trial targets cardiac surgery-associated acute kidney injury (CS-AKI).
  • RCH is the fourth active dosing site in Canada, with recruitment continuing at Toronto General, St. Michael’s Hospital, and University of Calgary.
  • Company is in feasibility discussions for four prospective sites in the United States and one additional site in Ontario.
  • Recruitment target remains 240 patients across a multi-center, randomized, double-blind, placebo-controlled study.
  • CEO Richard Muruve confirms steady progress toward establishing LSALT peptide as a new drug to reduce AKI incidence and dialysis needs.
Material Impact
  • The news represents expected clinical progression following the April 30 announcement that RCH began patient recruitment.
  • Dosing of the first patient is a standard operational milestone rather than a data readout or efficacy confirmation, limiting immediate upside potential.
  • No new safety concerns (SUSARs) were reported in previous updates, maintaining the status quo on risk profile.
  • The announcement does not alter the capital structure or financing needs immediately but confirms burn rate continues as expected for Phase II execution.
  • Given the stock price ($0.44) is significantly below the recent private placement price ($0.60 in April 2026), positive news has limited ability to reverse sentiment without data readouts.
ARCH · Price
Company Overview
  • Company: Arch Biopartners Inc., focused on therapies for acute kidney injury (AKI) and chronic kidney disease (CKD).
  • Flagship Project: LSALT peptide in Phase II trial for cardiac surgery-associated AKI (CS-AKI).
  • Secondary Asset: Cilastatin in Phase II trial for toxin-induced AKI.
  • Pipeline Expansion: CKD platform targeting IL-32 cytokine, acquired via Lipdro Therapeutics acquisition in November 2025.
  • Scientific Basis: LSALT targets DPEP1-mediated inflammation; preclinical data published in Cell (2019) and Science Advances (2022).
Read the original news release →

More from Arch Biopartners Inc.

Jun 04, 2026 · 07:41

Arch Biopartners Advances Dual AKI Pipeline Amid Steady Cash Burn and Dilutive Financing

Technical Study Apr 30, 2026 · 07:00

Arch Biopartners Clinical Execution Continues Amidst Severe Capital Erosion and Liquidity Concerns

Other Apr 02, 2026 · 05:45

Arch Biopartners Closes Non-Brokered Private Placement

Financings Mar 30, 2026 · 06:03

Arch Biopartners Closes $600K Lifeline as Stock Tests 52-Week Lows Amid Dilution and Trial Rollout

Financings Mar 24, 2026 · 09:13

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Production / Operations Mar 20, 2026 · 07:05

Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Other